Subscribe
clu
clu / iStockphoto.com
12 September 2017Americas

BMS and Pfizer reach settlement with Teva

Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Americas
BMS sues Mylan to block Reyataz generic
20 March 2015   Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Americas
BMS sues Mylan to block Reyataz generic
20 March 2015   Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More on this story

Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Americas
BMS sues Mylan to block Reyataz generic
20 March 2015   Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB